Rare Disease Platform

About Congenica

Congenica is a leading provider of clinical genomic interpretation software, trusted by national health systems and over 190 labs worldwide. Its AI-powered platform transforms raw next-generation sequencing (NGS) data into actionable clinical insights, primarily for rare diseases but with expanding capabilities in oncology and infectious disease. Founded in 2014 with deep roots in the UK's Genomics England initiatives, the company was acquired by SeqOne in 2025, combining forces to create a scaled, well-funded entity with significant clinical and technological heritage. Congenica operates a SaaS-based business model, generating revenue by providing its platform and associated clinical interpretation services to diagnostic laboratories.

Therapeutic Areas

Other Rare Genetic Disorders Drugs